Find stats on top websites
Business and Product Insights
Barricaid is a bone-anchored implant designed to close large annular defects following a lumbar discectomy. The key features include its FDA approval, demonstrating safety and efficacy in reducing reherniation and reoperation rates. It is designed to preserve more of the patient's disc. The device includes a titanium bone anchor which secures a polymer plug into the disc space, repairing and reconstructing the disc wall. Clinical studies demonstrate a significant reduction (approximately 50% in a Level I RCT) in reherniation and reoperative recurrence starting at 90 days post-surgery and extending through 5 years. Barricaid aims to offer a straightforward implantation procedure, involving measuring the annular defect, testing alignment, anchoring, and confirming positioning under fluoroscopy. By closing the hole left after discectomy, Barricaid helps prevent further disc material from escaping.
Product Portfolio
Barricaid Annular Closure Device
Barricaid Recurrent Disc Herniation Solution
Intrinsic Therapeutics Key Value Propositions
Barricaid offers spine surgeons a clinically proven solution to reduce reherniation and reoperation rates following discectomy, ultimately improving patient outcomes and reducing healthcare costs associated with repeat surgeries; its value lies in providing a tangible benefit supported by clinical evidence and FDA approval.
Intrinsic Therapeutics Brand Positioning
Barricaid positions itself as a solution for spine surgeons seeking to reduce reherniation and reoperation rates post-discectomy, leveraging its FDA approval and clinical evidence to offer improved patient outcomes and quality of life.
Top Competitors
Medtronic
Stryker
NuVasive
Customer Sentiments
Customer sentiment is likely positive among surgeons who have seen reduced reherniation rates and improved patient outcomes using Barricaid, while patients appreciate the potential for long-term pain relief and reduced risk of repeat surgeries, given the clinical trial data.
Actionable Insights
Focus marketing efforts on showcasing Barricaid's clinical evidence and cost-effectiveness to increase adoption among spine surgeons and hospital administrators.
Products and Features
Barricaid is a bone-anchored implant designed to close large annular defects following a lumbar discectomy. The key features include its FDA approval, demonstrating safety and efficacy in reducing reherniation and reoperation rates. It is designed to preserve more of the patient's disc. The device includes a titanium bone anchor which secures a polymer plug into the disc space, repairing and reconstructing the disc wall. Clinical studies demonstrate a significant reduction (approximately 50% in a Level I RCT) in reherniation and reoperative recurrence starting at 90 days post-surgery and extending through 5 years. Barricaid aims to offer a straightforward implantation procedure, involving measuring the annular defect, testing alignment, anchoring, and confirming positioning under fluoroscopy. By closing the hole left after discectomy, Barricaid helps prevent further disc material from escaping.
Barricaid Annular Closure Device - Product Description
Barricaid is an FDA-approved annular closure device designed for effective closure of large defects in the annulus. Its primary purpose is to preserve more of the patient's disc following discectomy procedures. By addressing large annular defects, Barricaid aims to reduce the risk of reherniation and improve long-term patient outcomes. The device is intended for use by physicians and surgeons specializing in spine surgery.
Pros
- Barricaid is the only FDA-approved annular closure device for closing large defects, giving it a unique selling proposition
- It is designed to preserve more of the patient's disc, which can lead to better long-term outcomes
- By closing large defects, Barricaid reduces the risk of reherniation after discectomy.
Cons
- The product description focuses solely on the benefits, lacking information about potential drawbacks
- Annular closure devices involve a surgical procedure, which carries inherent risks such as infection, nerve damage, or device malfunction
- The cost of the device and the surgical procedure might be a significant barrier for some patients or healthcare systems.
Alternatives
- Other annular closure devices may exist, but none are specifically mentioned as direct competitors with FDA approval for large defects
- Surgical techniques like discectomy alone, without annular closure, are common but may lead to reherniation
- Conservative treatments like physical therapy and pain management can be alternatives for patients who are not candidates for or choose to avoid surgery.
Company Updates
Latest Events at Intrinsic Therapeutics
Barricaid: Revolutionizing Herniated Disc Surgery
Herniated disc surgery patients benefit from Barricaid, offering a breakthrough solution to lower the risk of reherniation and reoperation in herniated disc ...
View sourceNational Barricade
National Barricade is the Seattle traffic sign rental & traffic barricade construction signs, cones & barriers to Seattle, Bellevue & Tacoma.
View sourceIntrinsic Therapeutics Announces New Category 1 CPT Code for ...
Oct 24, 2024 ... Intrinsic Therapeutics, Inc., the developer of the Barricaid, an FDA approved medical device proven to significantly reduce reherniations ...
View sourceANNULAR CLOSURE - Patient Education Brochure
This brochure will provide you with information about the Barricaid® Annular. Closure Device (ACD), also referred to as “Barricaid,” a new treatment intended.
View sourceTransform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
